載入...
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
PURPOSE: Targeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients with PAH have a deficiency of prostacyclin and prostacyclin synthase. Selexipag is an orally available and selective prostacyclin receptor (IP receptor) agonist. Selexipag...
Na minha lista:
| 發表在: | Am J Cardiovasc Drugs |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4452035/ https://ncbi.nlm.nih.gov/pubmed/25850750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-015-0117-4 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|